Predict your next investment

Corporation
janssenpharmaceutica.be

See what CB Insights has to offer

About Janssen Pharmaceutica

Janssen Pharmaceutica is a corporation based out of Belgium.

Janssen Pharmaceutica Headquarter Location

Belgium

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Janssen Pharmaceutica

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Janssen Pharmaceutica in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,013 items

Companies that have been granted at least 1 510(k)s by the FDA since 2014. Companies tagged as #FDA510(K)

Latest Janssen Pharmaceutica News

UNICEF signs agreement to supply 220 million doses for AU by 2022

Jul 9, 2021

The African Union established AVAT in November 2020 to deliver COVID-19 vaccines to the African continent, with a goal of vaccinating 60 per cent of each AU country’s population. UNICEF | New York | Updated: 09-07-2021 10:37 IST | Created: 09-07-2021 10:30 IST Representative Image Image Credit: ANI SHARE UNICEF has signed an agreement with Janssen Pharmaceutica NV to supply up to 220 million doses of the J&J single-dose vaccine for all 55 Member States of the African Union (AU) by the end of 2022. Some 35 million doses are to be delivered by the end of this year. The agreement between UNICEF and Janssen Pharmaceutica NV will help implement the Advance Purchase Commitment (APC) signed between the African Vaccine Acquisition Trust (AVAT) and Janssen in March of this year. That agreement secured an option to order another 180 million doses, bringing the maximum access up to a total of 400 million doses by the end of 2022. Advertisement The African Union established AVAT in November 2020 to deliver COVID-19 vaccines to the African continent, with a goal of vaccinating 60 per cent of each AU country's population. Under the plan, the African Export-Import Bank (Afreximbank) and AVAT have signed a cooperation agreement on behalf of the AU for the development of an Advance Procurement Commitment (APC) Framework to support Member State access to COVID-19 vaccines. UNICEF will procure and deliver COVID-19 vaccines on behalf of the AVAT initiative. Other partners include the Africa Centres for Disease Control and Prevention (Africa CDC) and the World Bank. While multiple vaccines are anticipated to be part of the initiative's portfolio, Janssen's single-dose vaccine is the first to be included. "African countries must have affordable and equitable access to COVID-19 vaccines as soon as possible. Vaccine access has been unequal and unfair, with less than 1 per cent of the population of the African continent currently vaccinated against COVID-19. This cannot continue," said UNICEF Executive Director Henrietta Fore. "UNICEF, with its long history of delivering vaccines all around the world, is supporting global COVID-19 vaccinations efforts through AVAT, COVAX, and other channels to maximize supply and access to vaccines." Drawing upon decades of experience as the largest single vaccine buyer in the world as it does annually for routine immunization, UNICEF is acting as a procurement and logistics agency on behalf of the AVAT partnership. UNICEF stands ready to facilitate the procurement, transport and delivery of vaccines as soon as they become available and the AU Member States are ready to receive them. With its extensive capabilities and decades of expertise in managing freight, insurance and transport of vaccines which require strict adherence to cold chain requirements, UNICEF will work with the vaccine industry, freight forwarders and transport companies to get the doses to the communities that need them. Janssen's COVID-19 vaccine received a WHO Emergency Use Listing (EUL) on 12 March and is relying on a global supply network to produce the vaccine. The latest site for production, Aspen Pharmacare in Gqeberha, South Africa, was approved by the WHO on 29 June. Deliveries of the vaccine are expected to begin later in the 3rd quarter of 2021, with allocations to be determined by the Africa CDC. The agreement comes as the African continent faces the steepest surge in COVID-19 cases yet, and vaccine supply challenges have left many countries with large unvaccinated populations. In addition to its role in this partnership, UNICEF is also a key implementing partner for the COVAX Facility led by Gavi, the Vaccine Alliance, WHO and CEPI. Under this initiative, UNICEF has contributed to the delivery of more than 100 million doses to 135 countries. UNICEF's role in procuring and delivering COVID-19 vaccines on behalf of AVAT will complement and supplement the shared COVAX goal of ensuring equitable access to quality-assured COVID-19 vaccines. "Vaccinating the world against COVID-19 , as the virus continues to spread and mutate, is one of the largest and most complex collective health undertakings the world has ever seen, and we need all hands on deck," said Fore. "In the race to defeat this virus, equity is not a 'nice to have — it's an absolute necessity. This pandemic has cost everyone something, and some people everything. Only together can we bring the suffering to an end." READ MORE ON:

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.